08.19.09
CSL Biotherapies, a subsidiary of CSL Limited, received licensure from the FDA for its newest vaccine filling and packaging facility in Kankakee, IL. The facility is part of an investment to expand CSL’s U.S. influenza vaccine production capabilities and includes a high-speed, single-dose vaccine syringe filling line. The company also recently signed an initial contract for at least $180 million to supply the U.S. Department of Health & Human Services (HHS) with Novel Influenza A (H1N1) antigen.
The facility will provide filling and packaging services for CSL Biotherapies’ influenza vaccine supply, which is manufactured in Australia, to the U.S. market. CSL completed production of its seasonal influenza vaccine, Afluria, in early July and will deliver more than eight million doses for the upcoming flu season. The majority of that delivery will be in thimerosal-free, prefilled syringes.
“The licensure of this facility enables CSL Biotherapies to rapidly deliver quality, ready-to-administer, flu vaccines to U.S. healthcare providers,” said Wally Casey, senior vice president and general manager of Kankakee operations. “This milestone demonstrates once more CSL’s expertise and commitment to addressing pressing U.S. public health needs. It also underscores our support to enhance vaccine administration safety through the use of ready-to-use prefilled syringes.”
Sign up today for Contracting & Outsourcing 2009!
contractpharma.com/2009conference
The facility will provide filling and packaging services for CSL Biotherapies’ influenza vaccine supply, which is manufactured in Australia, to the U.S. market. CSL completed production of its seasonal influenza vaccine, Afluria, in early July and will deliver more than eight million doses for the upcoming flu season. The majority of that delivery will be in thimerosal-free, prefilled syringes.
“The licensure of this facility enables CSL Biotherapies to rapidly deliver quality, ready-to-administer, flu vaccines to U.S. healthcare providers,” said Wally Casey, senior vice president and general manager of Kankakee operations. “This milestone demonstrates once more CSL’s expertise and commitment to addressing pressing U.S. public health needs. It also underscores our support to enhance vaccine administration safety through the use of ready-to-use prefilled syringes.”
Sign up today for Contracting & Outsourcing 2009!
contractpharma.com/2009conference